Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ, 07065, United States.
Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ, 07065, United States.
Anal Chim Acta. 2024 Nov 1;1328:343176. doi: 10.1016/j.aca.2024.343176. Epub 2024 Aug 28.
Charge heterogeneity is a critical quality attribute for therapeutic biologics including antibody-drug conjugates (ADCs). Developing an ion exchange chromatography (IEX) or an imaged capillary isoelectric focusing (icIEF) method for ADCs with high drug-to-antibody ratio (DAR) is challenging because of the increased hydrophobicity from the payload-linker, DAR heterogeneity, and payload-linker instability. A sub-optimal method can be poorly stability-indicating due to the inability to discern contributions from charge and size variants conjugated with different number of drugs/payloads. Systematic strategy and guidance on charge variant method development is highly desired for high DAR ADCs with various complex structures.
This work encompasses the development and optimization of icIEF methods for high DAR ADCs of various DAR values (4-8) and payload linker chemistry. Method optimization focuses on improving resolution and stability indicating capabilities and differentiating contributions from the protein and payload-linker. Types, proportion, and combination of solubilizers and carrier ampholytes, as well as focusing parameters were interrogated. Our findings show that the structural units of the linker, the DAR, and the payload chemistry prescribe the selection of buffer, solubilizer, and ampholyte. We demonstrate that a stronger denaturant or solubilizer is needed for high DAR ADCs with polyethylene glycol (PEG)-containing linker structure compared to peptide linker. For unstable payload-linker, buffer system enhances sample stability which is vital to method robustness. In addition, a longer isoelectric focusing time is necessary for an ADC than its corresponding antibody to reach optimal focusing.
To the best of our knowledge, this is the first comprehensive study on icIEF method development for charge variant determination of high DAR ADCs with unique physicochemical properties.
对于包括抗体药物偶联物(ADC)在内的治疗性生物制剂,荷质比(DAR)不均一是一个关键的质量属性。由于有效载荷-接头增加了疏水性、DAR 不均一性和有效载荷-接头的不稳定性,因此为具有高 DAR 的 ADC 开发离子交换色谱(IEX)或成像毛细管等电聚焦(icIEF)方法极具挑战性。由于无法区分与不同数量的药物/有效载荷结合的电荷和大小变体的贡献,因此方法优化可能无法很好地指示稳定性。对于具有各种复杂结构的高 DAR ADC,非常需要电荷变异体方法开发的系统策略和指导。
这项工作涵盖了开发和优化各种 DAR 值(4-8)和有效载荷接头化学的高 DAR ADC 的 icIEF 方法。方法优化侧重于提高分辨率和稳定性指示能力,并区分蛋白质和有效载荷接头的贡献。研究了各种类型、比例和组合的增溶剂和载体两性电解质,以及聚焦参数。我们的研究结果表明,接头的结构单元、DAR 和有效载荷化学决定了缓冲液、增溶剂和两性电解质的选择。我们证明,与肽接头相比,具有聚乙二醇(PEG)结构的接头的高 DAR ADC 需要更强的变性剂或增溶剂。对于不稳定的有效载荷接头,缓冲液系统可增强样品稳定性,这对方法的稳健性至关重要。此外,与相应的抗体相比,ADC 达到最佳聚焦需要更长的等电聚焦时间。
据我们所知,这是第一项关于具有独特物理化学性质的高 DAR ADC 电荷变异体测定的 icIEF 方法开发的全面研究。